Long
Big data in the healthcare sector $INOV
$NASDAQ:INOV finally good technicals. Price above its 10, 20, 50 and 200 day MAs, 3 months with good buying volume and breakout from a cup and handle pattern. This are all the kind of technicals I need to see to consider a stock.
Now I went on to check the fundamentals and according to Reuters, $NASDAQ:INOV has a Gross Margin of 74.86%, that's pretty good for the industry. Has a nice uptrend in revenue, 56% growth since 2016 and last quarter had a 1.300% EPS growth, that's a big jump.
Also, is rank #1 in the IBD industry ranking with a Relative Strenght Rating of 74. This is the kind of technicals and fundamentals combination I like to see in a stock.
Now I went on to check the fundamentals and according to Reuters, $NASDAQ:INOV has a Gross Margin of 74.86%, that's pretty good for the industry. Has a nice uptrend in revenue, 56% growth since 2016 and last quarter had a 1.300% EPS growth, that's a big jump.
Also, is rank #1 in the IBD industry ranking with a Relative Strenght Rating of 74. This is the kind of technicals and fundamentals combination I like to see in a stock.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.